BioPharmSignal logoBioPharmSignal

Biotech News

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Ibio Inc (IBIO)Ibio IncConference / presentation

IBIO (IBIO) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ibio.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

IBIOIbio Inc2025-10-23 11:00 EST

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

IBIOIbio Inc2026-06-02 11:00 EST

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

ENTXEntera Bio2026-07-31 20:30 EST

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

CHRSCoherus BioSciences, Inc.2026-01-06 14:30 EST

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

ADMAADMA Biologics2026-01-05 12:00 EST

ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

MDXGMiMedx2026-05-21 12:45 EST

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

CHRSCoherus BioSciences, Inc.2026-02-23 14:30 EST

Coherus Oncology to Participate in Upcoming Investor Conferences

STTKShattuck Labs2025-04-02 21:00 EST

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

RXRXRecursion2026-01-06 12:59 EST

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

ENTXEntera Bio2025-06-25 12:00 EST

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

View all latest news

Ibio Inc

AI-Enabled Antibody Discovery iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties. IBIO-600 IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment. Cardiopulmonary...

Recent company news

IBIOIbio Inc2026-08-04 11:00 EST

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

IBIOIbio Inc2026-07-01 11:00 EST

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

IBIOIbio Inc2026-06-02 20:01 EST

iBio to Participate in Upcoming Healthcare Investor Conferences

IBIOIbio Inc2026-06-02 11:00 EST

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

IBIOIbio Inc2026-05-12 20:05 EST

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

Stock data

Close
1.39 USD
Market cap
87.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States